Sugi Predict

Sugi Predict / Compounds / SCHEMBL3711933

SCHEMBL3711933

SCHEMBL3711933

CCNC(=O)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ROCK1 Q13464 1/20 0.46
▸ LIPG Q9Y5X9 7/20 0.42
▸ LPL P06858 6/20 0.42
▸ CA1 P00915 4/20 0.40
▸ CA2 P00918 4/20 0.40
▸ CA9 Q16790 4/20 0.40
▸ HIF1A Q16665 2/20 0.39
▸ LMNA P02545 1/20 0.37
▸ F2 P00734 1/20 0.36
▸ F11 P03951 1/20 0.36
▸ PRSS1 P07477 1/20 0.36
▸ PRSS2 P07478 1/20 0.36
▸ PRSS3 P35030 1/20 0.36
▸ PRMT5 O14744 1/20 0.36
▸ WDR77 Q9BQA1 1/20 0.36
▸ BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31275224 0.86 ROCK1 (0.48) ROCK1LIPGLPLCA1CA2
SCHEMBL455814 0.85 LIPG (0.43) ROCK1LIPGLPLCA1CA2
SCHEMBL25676833 0.85 ROCK1 (0.46) ROCK1LIPGLPLCA1CA2
SCHEMBL15594472 0.85 ROCK1 (0.46) ROCK1LIPGLPLCA1CA2
SCHEMBL16679886 0.84 HTT (0.49) ROCK1LIPGCA1CA2CA9
SCHEMBL28981113 0.84 CNR2 (0.47) ROCK1CA1CA2CA9HIF1A
SCHEMBL21217812 0.84 LIPG (0.40) ROCK1LIPGLPLCA1CA2
SCHEMBL22967051 0.82 ROCK1 (0.40) ROCK1LIPGLPLCA1CA2
SCHEMBL793338 0.82 ROCK1 (0.48) ROCK1LIPGLPLCA1CA2
SCHEMBL31275320 0.82 ROCK1 (0.43) ROCK1LIPGLPLCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2026-02-05 — — US disclosed
US-12453734-B2 Modulators of rho-associated protein kinase REDX PHARMA LIMITED (GB) 2025-10-28 — — US disclosed
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2024-07-04 — — US disclosed
US-11878020-B2 Modulators of Rho-associated protein kinase REDX PHARMA PLC (GB) 2024-01-23 — — US disclosed
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2023-01-26 — — US disclosed
US-11497751-B2 Modulators of Rho-associated protein kinase REDX PHARMA PLC (GB) 2022-11-15 — — US disclosed
EP-4026834-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2022-07-13 — — EP disclosed
EP-3743420-B1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA PLC (GB) 2021-12-15 — — EP disclosed
US-20210038606-A1 Modulators of Rho-associated Protein Kinase REDX PHARMA LIMITED (GB) 2021-02-11 — — US disclosed
EP-3743420-A1 HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Plc (GB) 2020-12-02 — — EP disclosed
EP-2892904-B1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS CB THERAPEUTICS INC (KY) 2018-10-17 — — EP disclosed
US-9695175-B2 Highly selective c-Met inhibitors as anticancer agents CB THERAPEUTICS INC. (KY) 2017-07-04 — — US disclosed
US-9695175-B2 Highly selective c-Met inhibitors as anticancer agents CB THERAPEUTICS INC. (KY) 2017-07-04 — — US disclosed
US-9695175-B2 Highly selective c-Met inhibitors as anticancer agents CB THERAPEUTICS INC. (KY) 2017-07-04 — — US disclosed
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS APOLLOMICS INC. 2015-08-06 — — US disclosed
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS APOLLOMICS INC. 2015-08-06 — — US disclosed
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS APOLLOMICS INC. 2015-08-06 — — US disclosed
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists PROSIDION LIMITED (GB) 2011-03-10 — — US disclosed
EP-2215077-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS Prosidion Limited (GB) 2010-08-11 — — EP disclosed
WO-2009050522-A1 AZETIDINYL G-PROTEIN COUPLED RECEPTOR AGONISTS PROSIDION LIMITED (GB) 2009-04-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034140-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA ROCK1 1/4885LIPG 3729/4885LPL 4431/4885
US-20150218171-A1 HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS MET, MYC, HGFAC ROCK1 906/4885LIPG 2891/4885LPL 4640/4885
US-12453734-B2 Modulators of rho-associated protein kinase ROCK2, ROCK1, RHOA ROCK1 2/4885LIPG 1476/4885LPL 4067/4885
US-20240216386-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA ROCK1 2/4885LIPG 1476/4885LPL 4067/4885
US-11497751-B2 Modulators of Rho-associated protein kinase ROCK2, ROCK1, RHOA ROCK1 2/4885LIPG 1655/4885LPL 4093/4885
US-20210038606-A1 Modulators of Rho-associated Protein Kinase ROCK2, ROCK1, RHOA ROCK1 2/4885LIPG 1655/4885LPL 4093/4885
US-11878020-B2 Modulators of Rho-associated protein kinase ROCK2, ROCK1, RHOA ROCK1 2/4885LIPG 1476/4885LPL 4067/4885
US-20110059942-A1 Azetidinyl G-Protein Coupled Receptor Agonists GPR119, GIPR, GPR39 ROCK1 3990/4885LIPG 620/4885LPL 453/4885
US-20230021916-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK2, ROCK1, RHOA ROCK1 2/4885LIPG 1476/4885LPL 4067/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.